Laboratory synthesis of p-chlorophenyl-L-cysteine and its acetylation by the rat.

H. D. West,G. Mathura,L. Black

DOI: https://doi.org/10.1016/s0021-9258(19)52435-8

IF: 5.485

1951-11-01

Journal of Biological Chemistry

Abstract:

What problem does this paper attempt to address?

B Lymphocytes Ameliorate Alzheimer’s Disease-Like Neuropathology Via Interleukin-35

Weixi Feng,Yanli Zhang,Shixin Ding,Sijia Chen,Tianqi Wang,Ze Wang,Ying Zou,Chengyu Sheng,Yan Chen,Yingting Pang,Charles Marshall,Jingping Shi,Maiken Nedergaard,Qian Li,Ming Xiao

DOI: https://doi.org/10.1016/j.bbi.2022.11.012

IF: 19.227

2022-01-01

Brain Behavior and Immunity

Abstract:Increasing evidence supports the involvement of the peripheral immune system in the pathogenesis of Alzheimer's disease (AD). In the present study, we found that B lymphocytes could mitigate beta-Amyloid (Aβ) pathology and memory impairments in a transgenic AD mouse model. Specifically, in young 5 × FAD mice, we evidenced increased B cells in the frontal cortex and meningeal tissues; depletion of mature B cells aggravated these mice's Aβ load and memory deficits. The increased B cells produced more interleukin-35 (IL-35) in the front cortex. We further found IL-35 neutralization exacerbated Aβ pathology, while injecting IL-35 mitigated Aβ load and cognitive dysfunction in 5 × FAD mice with or without mature B cell deficiency. Mechanistically, IL-35 inhibited neuronal BACE1 transcription through modulating the SOCS1/STAT1 pathway, and reduced Aβ production accordingly. Reanalysis of the single-cell RNA sequencing data from blood samples of AD patients suggested an increased population of IL-35-producing B cells. Together, the present study revealed a novel effect of B lymphocyte-derived IL-35 on inhibiting Aβ production in the frontal cortex, which may serve as a potential target for future AD treatment.
Pulmonary B Lymphocytes Ameliorate Alzheimer's Disease-Like Neuropathology

Weixi Feng,Yanli Zhang,Tianqi Wang,Qian Li,Ze Wang,Ying Zou,Chengyu Sheng,Yan Chen,Yingting Pang,Fengfei Ding,Charles Marshall,Jingping Shi,Maiken Nedergaard,Ming Xiao

DOI: https://doi.org/10.21203/rs.3.rs-713746/v1

2021-01-01

Abstract:Increasing evidences reveal that the peripheral immune system is involved in the pathogenesis of Alzheimer's disease (AD). Here, we report that pulmonary B lymphocytes mitigate beta-Amyloid (Aβ) pathology in 5xFAD mice. The proportion of B cells, rather than T cells, increases within the brain, meningeal and lung tissues in 3-month-old 5xFAD mice. Deletion of mature B cells aggravates Aβ load and memory deficits of 5xFAD mice. Mechanistically, pulmonary B cells can migrate to the brain parenchyma and produce interleukin-35, which inhibits neuronal β-site APP-cleaving enzyme 1 expression, and subsequently reduces the production of Aβ. In turn, pulmonary B cell proliferation is associated with activation of the toll-like receptor/nuclear factor kappa-B pathway through elevated Aβ that is drained from the brain parenchyma to the lungs via meningeal lymphatics. Furthermore, promoting pulmonary B cell proliferation via overexpression of B-cell-activating factor ameliorates brain Aβ load and improves cognitive functions of 10-month-old 5xFAD mice. Together, these results highlight the lungs as both immune targets and effector organs in Aβ pathogenesis. Pulmonary B cells could serve as a potential target against AD.
Pulmonary B cells ameliorate Alzheimer’s disease-like neuropathology

Weixi Feng,Yanli Zhang,Tianqi Wang,Ze Wang,Yan Chen,Chengyu Sheng,Ying Zou,Yingting Pang,Junying Gao,Yongjie Zhang,Jingping Shi,Qian Li,Ming Xiao

DOI: https://doi.org/10.1101/2020.11.23.393942

2020-01-01

Abstract:Increasing evidence shows that the peripheral immune system is involved in the pathogenesis of Alzheimer’s disease (AD). Here, we report that pulmonary B cells mitigate beta-Amyloid (Aβ) pathology in 5xFAD mice. The proportion of B cells rather than T cells increases in brain, meningeal and lung tissues in 3-month-old 5xFAD mice. Deletion of B cells aggravates Aβ load and memory deficits of 5xFAD mice. Mechanimsly, pulmonary B cells can migrate to the brain parenchyma and produce interleukin-35 that inhibits neuronal β-site APP-cleaving enzyme 1 expression, subsequently reducing the production of Aβ. In turn, proliferation of pulmonary B cells is associated with activation of toll-like receptor/nuclear factor kappa-B pathway by elevated Aβ that is drained from the brain parenchyma to the lungs via meningeal lymphatics. Furthermore, promoting pulmonary B cell proliferation via overexpression of B-cell-activating factor ameliorates brain Aβ load and improves cognitive functions of 10-month-old 5xFAD mice. Together, these results highlight the lungs as both immune targets and effector organs in Aβ pathogenesis. Pulmonary B cells might be a potential target against AD. ### Competing Interest Statement The authors have declared no competing interest.
A butyrolactone derivative 3BDO alleviates memory deficits and reduces amyloid-β deposition in an AβPP/PS1 transgenic mouse model.

LiFei Wei,Hui Yang,ZhaoHong Xie,ShaoNan Yang,HongNa Yang,CuiPing Zhao,Ping Wang,ShunLiang Xu,JunYing Miao,BaoXiang Zhao,JianZhong Bi

DOI: https://doi.org/10.3233/JAD-2012-111985

2012-01-01

Journal of Alzheimer s Disease

Abstract:Excessive extracellular deposition of amyloid- peptide (Aβ) in the brain is the pathological hallmark of Alzheimer's disease (AD). Cumulative evidence indicates that autophagy is involved in the metabolism of Aβ and pathogenesis of AD. However, the molecular mechanism underlying the pathogenesis of AD is not yet well defined, and there has been no effective treatment for AD. We recently found that long-term treatment with a butyrolactone derivative 3-benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran- 2(3 H)-one (3BDO) increased levels of insulin-degrading enzyme and neprilysin, suppressed autophagy via an mTOR pathway, lowered levels of Aβ, and prevented AD-like cognitive deficits in the AβPP/PS1 double transgenic mouse model. Therefore, our findings suggest that 3BDO may be beneficial in the prevention and treatment of AD.
Amelioration of Experimental Autoimmune Encephalomyelitis in Alzheimer’s Disease Mouse Models: A Potential Role for Aβ

Changjie Shi,Jiaxue Cha,Junyuan Gong,Shaodeng Wang,Peng Zeng,Junjiang Lian,Bowen Zhang,Qiuhong Hua,Jie Lv,Changsheng Du,Xin Xie,Ru Zhang

DOI: https://doi.org/10.3390/cells11061004

IF: 6

2022-03-16

Cells

Abstract:Emerging data have highlighted the coexistence of multiple sclerosis (MS) and Alzheimer’s disease (AD), both of which are common central nervous system degenerative diseases with a heavy burden on patients, their families, and society. However, it is unclear how MS progresses under an AD pathological background. We aimed to address the question of how MS progresses under an AD pathological background. We induced the experimental autoimmune encephalomyelitis (EAE) model of MS in two types of AD mouse models, Tg6799 and APP/PS1 mice. We found that, compared with wild-type mice, the clinical symptoms of EAE were significantly ameliorated in APP/PS1 mice but not in Tg6799 mice. Moreover, a much lower level of serum Aβ was observed in Tg6799 mice. EAE clinical symptoms in Tg6799 and C57BL/6J mice were ameliorated by intraperitoneal injection of Aβ42. Peripheral administration of Aβ42 peptides was able to inhibit Th17 development in vivo, which is likely to occur through the inhibition of IL-6 production in dendritic cells. Our findings revealed that AD and EAE could coexist in the same mouse, and Aβ residing in peripheral circulation likely plays an anti-inflammatory role in preventing EAE progression. These findings reveal the potential benefit of Aβ, one of the supervillains of AD, at least in certain contexts.

cell biology
The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function

Samuel E. Marsh,Edsel M. Abud,Anita Lakatos,Alborz Karimzadeh,Stephen T. Yeung,Hayk Davtyan,Gianna M. Fote,Lydia Lau,Jason G. Weinger,Thomas E. Lane,Matthew A. Inlay,Wayne W. Poon,Mathew Blurton-Jones

DOI: https://doi.org/10.1073/pnas.1525466113

IF: 11.1

2016-02-16

Proceedings of the National Academy of Sciences

Abstract:Significance Neuroinflammation and activation of innate immunity are pathological hallmarks of Alzheimer’s disease (AD). In contrast, very few studies have examined the impact of the adaptive immune system in AD pathogenesis. Here, we find that genetic ablation of peripheral immune cell populations significantly accelerates amyloid pathogenesis, worsens neuroinflammation, and alters microglial activation state. Critically, it appears that loss of IgG-producing B cells impairs microglial phagocytosis, thereby exacerbating amyloid deposition. Conversely, replacement of IgGs via direct injection or bone marrow transplantation reverses these effects and reduces Aβ pathology. Together, these results highlight the importance of the adaptive immune system and its interactions with microglia in the pathogenesis of AD.
Single-cell RNA sequencing reveals B cell–related molecular biomarkers for Alzheimer’s disease

Liu-Lin Xiong,Lu-Lu Xue,Ruo-Lan Du,Rui-Ze Niu,Li Chen,Jie Chen,Qiao Hu,Ya-Xin Tan,Hui-Fang Shang,Jia Liu,Chang-Yin Yu,Ting-Hua Wang

DOI: https://doi.org/10.1038/s12276-021-00714-8

2021-12-01

Abstract:Abstract In recent years, biomarkers have been integrated into the diagnostic process and have become increasingly indispensable for obtaining knowledge of the neurodegenerative processes in Alzheimer’s disease (AD). Peripheral blood mononuclear cells (PBMCs) in human blood have been reported to participate in a variety of neurodegenerative activities. Here, a single-cell RNA sequencing analysis of PBMCs from 4 AD patients (2 in the early stage, 2 in the late stage) and 2 normal controls was performed to explore the differential cell subpopulations in PBMCs of AD patients. A significant decrease in B cells was detected in the blood of AD patients. Furthermore, we further examined PBMCs from 43 AD patients and 41 normal subjects by fluorescence activated cell sorting (FACS), and combined with correlation analysis, we found that the reduction in B cells was closely correlated with the patients’ Clinical Dementia Rating (CDR) scores. To confirm the role of B cells in AD progression, functional experiments were performed in early-stage AD mice in which fibrous plaques were beginning to appear; the results demonstrated that B cell depletion in the early stage of AD markedly accelerated and aggravated cognitive dysfunction and augmented the Aβ burden in AD mice. Importantly, the experiments revealed 18 genes that were specifically upregulated and 7 genes that were specifically downregulated in B cells as the disease progressed, and several of these genes exhibited close correlation with AD. These findings identified possible B cell-based AD severity, which are anticipated to be conducive to the clinical identification of AD progression.

biochemistry & molecular biology,medicine, research & experimental
IL-33 ameliorates Alzheimer’s disease-like pathology and cognitive decline

Amy K. Y. Fu,Kwok-Wang Hung,Michael Y. F. Yuen,Xiaopu Zhou,Deejay S. Y. Mak,Ivy C. W. Chan,Tom H. Cheung,Baorong Zhang,Wing-Yu Fu,Foo Y. Liew,Nancy Y. Ip

DOI: https://doi.org/10.1073/pnas.1604032113

IF: 11.1

2016-04-18

Proceedings of the National Academy of Sciences

Abstract:Significance Dysfunction of the innate immune system is involved in the pathogenesis of Alzheimer’s disease (AD); however, the pathophysiological mechanisms underlying these dysfunctions are unclear. Here we report that stimulation of IL-33/ST2 signaling rescues memory deficits and reduces the accumulation of β-amyloid in APP/PS1 mice that exhibit select pathologies associated with AD. Although impaired IL-33/ST2 signaling is associated with early progression of AD, IL-33 injection rescues contextual memory deficits and reduces the accumulation of β-amyloid in APP/PS1 mice. IL-33 skews the microglia toward an alternative activation state with enhanced Aβ phagocytic capacity and elevated antiinflammatory gene expression, which results in a decreased proinflammatory response in the brain. Thus, this study suggests that IL-33 can be developed as a new therapeutic intervention for AD.
Interferon Regulatory Factor 5 Regulates the Phagocytosis of Microglia and Alleviate Alzheimer's Pathology.

Ziqi Fan,Xinyi Zhang,Shuai Zhao,Siyan Zhong,Zheyu Li,Yaping Yan,Baorong Zhang,Yanxing Chen

DOI: https://doi.org/10.1093/gerona/glae031

2024-01-01

The Journals of Gerontology Series A

Abstract:Microglia play a critical role in the pathophysiology of Alzheimer's disease. They are involved in A beta-induced neuroinflammatory responses, regulating the production of inflammatory mediators. Interferon regulatory factor 5 (IRF5) plays a central role in inflammatory diseases in the periphery, the role of which in central nervous system remains elusive. This study aimed to investigate the role of IRF5 in A beta-induced neuroinflammation and the progression of A beta pathology. We found that A beta 1-42 oligomers significantly increased the level of IRF5 in BV2 microglia. The levels of proinflammatory cytokines TNF-alpha, IL-1 beta, and IL-6 were significantly upregulated with A beta treatment. IRF5 knockdown with siRNA in microglia significantly reduced the expression of these proinflammatory factors induced by A beta and promoted A beta phagocytosis. Besides, LC3 upregulation and p62 downregulation were observed in IRF5 knockdown microglia. This was also validated in APP/PS1 mice with IRF5 knockdown, leading to reduced A beta levels in the brain. We conclude that IRF5 mediates A beta-induced microglial inflammatory responses. IRF5 knockdown attenuated A beta-induced inflammatory responses and promoted the phagocytosis and autophagy of A beta by microglia.
Single-cell transcriptomics reveals colonic immune perturbations during amyloid-β driven Alzheimer's disease in mice

Priya Makhijani,Rohini Emani,Carlos Galicia Aguirre,Wei-Chieh Mu,Anand Rane,Jenny Hong Yu Ng,Taylor R Valentino,Max Manwaring-Mueller,Christopher Ryan Tan,Huixun Du,Fei Wu,Saad Khan,Kenneth A Wilson,Shawn Winer,Chao Wang,Arthur Mortha,David Furman,Lisa M Ellerby,Olga L Rojas,Julie K Andersen,Daniel A Winer

DOI: https://doi.org/10.1101/2024.01.27.573841

2024-01-30

bioRxiv

Abstract:The "gut-brain axis" is emerging as an important target in Alzheimer's disease (AD). However, immunological mechanisms underlying this axis remain poorly understood. Using single-cell RNA sequencing of the colon immune compartment in the 5XFAD amyloid-β (Aβ) mouse model, we uncovered AD-associated changes in ribosomal activity, oxidative stress, and BCR/plasma cell activity. Strikingly, levels of colon CXCR4 + antibody secreting cells (ASCs) were significantly reduced. This corresponded with accumulating CXCR4 + B cells and gut-specific IgA + cells in the brain and dura mater, respectively. Consistently, a chemokine ligand for CXCR4, CXCL12, was expressed at higher levels in 5XFAD glial cells and in in silico analyzed human brain studies, supporting altered neuroimmune trafficking. An inulin prebiotic fiber diet attenuated AD markers including Aβ plaques and overall frailty. These changes corresponded to an expansion of gut IgA + cells and rescued peripheral T regs levels. Our study points to a key glia-gut axis and potential targets against AD. Study highlights: AD is associated with altered immune parameters in the gut of 5XFAD mice. 5 XFAD colon has reduced ASCs, including CXCR4 + cells with a migratory gene signature. 5XFAD brain gliosis includes increased CXCL12 expression. CXCR4 + B cells and gut-specific IgA + ASCs accumulate in the 5XFAD brain and/or dura mater. Inulin diet attenuates AD disease parameters while boosting IgA + cell and T reg levels.
Rejuvenation of peripheral immune cells attenuates Alzheimer's disease-like pathologies and behavioral deficits in a mouse model

Pu-Yang Sun,Jie Liu,Jian-Ni Hu,Yun-Feng Tu,Qiu Jiang,Yu-Juan Jia,Hao-Lun Sun,Si-Han Chen,Jia-Yan Xin,Zhong-Yuan Yu,Zhi-Hao Liu,Cheng-Rong Tan,Gui-Hua Zeng,An-Yu Shi,Yu-Hui Liu,Xian-Le Bu,Yan-Jiang Wang,Jun Wang

DOI: https://doi.org/10.1126/sciadv.adl1123

IF: 13.6

2024-05-30

Science Advances

Abstract:Immunosenescence contributes to systematic aging and plays a role in the pathogenesis of Alzheimer's disease (AD). Therefore, the objective of this study was to investigate the potential of immune rejuvenation as a therapeutic strategy for AD. To achieve this, the immune systems of aged APP/PS1 mice were rejuvenated through young bone marrow transplantation (BMT). Single-cell RNA sequencing revealed that young BMT restored the expression of aging- and AD-related genes in multiple cell types within blood immune cells. The level of circulating senescence-associated secretory phenotype proteins was decreased following young BMT. Notably, young BMT resulted in a significant reduction in cerebral Aβ plaque burden, neuronal degeneration, neuroinflammation, and improvement of behavioral deficits in aged APP/PS1 mice. The ameliorated cerebral amyloidosis was associated with an enhanced Aβ clearance of peripheral monocytes. In conclusion, our study provides evidence that immune system rejuvenation represents a promising therapeutic approach for AD.

multidisciplinary sciences
The Combined Treatment of Amyloid-Β1-42-stimulated Bone Marrow–derived Dendritic Cells Plus Splenocytes from Young Mice Prevents the Development of Alzheimer's Disease in APPswe/PSENldE9 Mice

Fei Wang,Hanqiu Liu,Xueyan Shen,Hong Ao,Nick Moore,Lingling Gao,Long Chen,Heng Hua,Huiying Maa,Zixiao Yang,Chunxiao Zhai,Jie Qin,Guomin Zhou,Yuwen Peng,Xiaoyuan Feng,Ruixi Li,Chunmin Liang

DOI: https://doi.org/10.1016/j.neurobiolaging.2014.06.029

IF: 5.133

2014-01-01

Neurobiology of Aging

Abstract:Anti-amyloid-β (Aβ) immunotherapy is a potential therapeutic strategy to reduce amyloid plaques and amyloid-associated pathologies in Alzheimer's disease (AD). Immune senescence with aging has also played a crucial role in AD pathogenesis and influences the effect of anti-Aβ immunotherapy. In this study, a combined treatment of Aβ₁₋₄₂-bone marrow-derived dendritic cells (BMDCs) with intraperitoneal injection of splenocytes from young mice was designed as a novel immunotherapy for AD in APPswe/PSEN1de9 transgenic mice models. The results showed that the combined treatment not only elevated the level of anti-Aβ antibodies but also reduced amyloid plaques in brain and finally ameliorated deterioration of spatial learning and memory in AD mice. Additionally, the results revealed an increase of CD68 positive microglial cells in the vicinity of amyloid plaques in the mouse brain, which was responsible for the enhanced phagocytosis of Aβ plaques. In conclusion, the Aβ₁₋₄₂-BMDCs plus splenocytes treatment improved the phagocytosis of microglia and prevented AD pathology more effectively. This combined immunotherapy provided a promising treatment in preventing the progression of AD in clinical studies in the near future.
CD8 + T cells exacerbate AD-like symptoms in mouse model of amyloidosis

Xin Wang,Britney Campbell,Monica Bodogai,Ross A. McDevitt,Anton Patrikeev,Fedor Gusev,Emeline Ragonnaud,Konda Kumaraswami,Sophie Shirenova,Karin Vardy,Mohamed-Gabriel Alameh,Drew Weissman,Hellen Ishikawa-Ankerhold,Eitan Okun,Evgeny Rogaev,Arya Biragyn

DOI: https://doi.org/10.1016/j.bbi.2024.08.045

IF: 19.227

2024-08-30

Brain Behavior and Immunity

Abstract:Alzheimer's disease (AD) is linked to toxic Aβ plaques in the brain and activation of innate responses. Recent findings however suggest that the disease may also depend on the adaptive immunity, as B cells exacerbate and CD8^(+) T cells limit AD-like pathology in mouse models of amyloidosis. Here, by artificially blocking or augmenting CD8^(+) T cells in the brain of 5xFAD mice, we provide evidence that AD-like pathology is promoted by pathogenic, proinflammatory cytokines and exhaustion markers...

immunology,neurosciences,psychiatry
T cell infiltration mediates neurodegeneration and cognitive decline in Alzheimer's disease

Junjian Zeng,Zhiqiang Liao,Hanqin Yang,Qiong Wang,Zhiyong Wu,Fuzhou Hua,Zhidong Zhou

DOI: https://doi.org/10.1016/j.nbd.2024.106461

IF: 7.046

2024-03-04

Neurobiology of Disease

Abstract:Alzheimer's disease (AD) is a prevalent neurodegenerative disorder with pathological features of β-amyloid (Aβ) and hyperphosphorylated tau protein accumulation in the brain, often accompanied by cognitive decline. So far, our understanding of the extent and role of adaptive immune responses in AD has been quite limited. T cells, as essential members of the adaptive immune system, exhibit quantitative and functional abnormalities in the brains of AD patients. Dysfunction of the blood-brain barrier (BBB) in AD is considered one of the factors leading to T cell infiltration. Moreover, the degree of neuronal loss in AD is correlated with the quantity of T cells. We first describe the differentiation and subset functions of peripheral T cells in AD patients and provide an overview of the key findings related to BBB dysfunction and how T cells infiltrate the brain parenchyma through the BBB. Furthermore, we emphasize the risk factors associated with AD, including Aβ, Tau protein, microglial cells, apolipoprotein E (ApoE), and neuroinflammation. We discuss their regulation of T cell activation and proliferation, as well as the connection between T cells, neurodegeneration, and cognitive decline. Understanding the innate immune response is crucial for providing comprehensive personalized therapeutic strategies for AD.

neurosciences
Robotic Long-distance Telementoring in Neurosurgery

Ivar M Mendez,Ron Hill,D. Clarke,G. Kolyvas,S. Walling

DOI: https://doi.org/10.1227/01.NEU.0000153928.51881.27

IF: 5.315

2005-03-01

Neurosurgery

Abstract:OBJECTIVE:To test the feasibility of long-distance telementoring in neurosurgery by providing subspecialized expertise in real time to another neurosurgeon performing a surgical procedure in a remote location. METHODS:A robotic telecollaboration system (Socrates; Computer Motion, Inc., Santa Barbara, CA) capable of controlling the movements of a robotic arm, of handling two-way video, and of audio communication as well as transmission of neuronavigational data from the remote operating room was used for the telementoring procedures. Four integrated services digital network lines with a total speed of transmission of 512 kilobytes per second provided telecommunications between a large academic center (Halifax, Nova Scotia) and a community-based center (Saint John, New Brunswick) located 400 km away. RESULTS:Long-distance telementoring was used in three craniotomies for brain tumors, a craniotomy for an arteriovenous malformation, a carotid endarterectomy, and a lumbar laminectomy. There were no surgical complications during the procedures, and all patients had uneventful outcomes. The neurosurgeons in the remote location believed that the input from the mentors was useful in all of the cases and was crucial in the removal of a mesial temporal lobe glioma and resection of an occipital arteriovenous malformation. CONCLUSION:Our initial experience with long-distance robotic-assisted telementoring in six cases indicates that telementoring is feasible, reliable, and safe. Although still in its infancy, telementoring has the potential to improve surgical care, to enhance neurosurgical training, and to have a major impact on the delivery of neurosurgical services throughout the world.
Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model

Jinchao Hou,Yun Chen,Zhangying Cai,Gyu Seong Heo,Carla M Yuede,Zuoxu Wang,Kent Lin,Fareeha Saadi,Tihana Trsan,Aivi T Nguyen,Eleni Constantopoulos,Rachel A Larsen,Yiyang Zhu,Nicole D Wagner,Nolan McLaughlin,Xinyi Cynthia Kuang,Alexander D Barrow,Dian Li,Yingyue Zhou,Shoutang Wang,Susan Gilfillan,Michael L Gross,Simone Brioschi,Yongjian Liu,David M Holtzman,Marco Colonna

DOI: https://doi.org/10.1126/scitranslmed.adj9052

2024-04-03

Abstract:Microglia help limit the progression of Alzheimer's disease (AD) by constraining amyloid-β (Aβ) pathology, effected through a balance of activating and inhibitory intracellular signals delivered by distinct cell surface receptors. Human leukocyte Ig-like receptor B4 (LILRB4) is an inhibitory receptor of the immunoglobulin (Ig) superfamily that is expressed on myeloid cells and recognizes apolipoprotein E (ApoE) among other ligands. Here, we find that LILRB4 is highly expressed in the microglia of patients with AD. Using mice that accumulate Aβ and carry a transgene encompassing a portion of the LILR region that includes LILRB4, we corroborated abundant LILRB4 expression in microglia wrapping around Aβ plaques. Systemic treatment of these mice with an anti-human LILRB4 monoclonal antibody (mAb) reduced Aβ load, mitigated some Aβ-related behavioral abnormalities, enhanced microglia activity, and attenuated expression of interferon-induced genes. In vitro binding experiments established that human LILRB4 binds both human and mouse ApoE and that anti-human LILRB4 mAb blocks such interaction. In silico modeling, biochemical, and mutagenesis analyses identified a loop between the two extracellular Ig domains of LILRB4 required for interaction with mouse ApoE and further indicated that anti-LILRB4 mAb may block LILRB4-mApoE by directly binding this loop. Thus, targeting LILRB4 may be a potential therapeutic avenue for AD.
Single-Cell RNA Sequencing of Peripheral Blood Reveals Immune Cell Signatures in Alzheimer’s Disease

Hui Xu,Jianping Jia

DOI: https://doi.org/10.3389/fimmu.2021.645666

IF: 7.3

2021-08-09

Frontiers in Immunology

Abstract:The peripheral immune system is thought to affect the pathology of the central nervous system in Alzheimer’s disease (AD). However, current knowledge is inadequate for understanding the characteristics of peripheral immune cells in AD. This study aimed to explore the molecular basis of peripheral immune cells and the features of adaptive immune repertoire at a single cell level. We profiled 36,849 peripheral blood mononuclear cells from AD patients with amyloid-positive status and normal controls with amyloid-negative status by 5’ single-cell transcriptome and immune repertoire sequencing using the cell ranger standard analysis procedure. We revealed five immune cell subsets: CD4+ T cells, CD8+ T cells, B cells, natural killer cells, and monocytes–macrophages cells, and disentangled the characteristic alterations of cell subset proportion and gene expression patterns in AD. Thirty-one cell type-specific key genes, comprising abundant human leukocyte antigen genes, and multiple immune-related pathways were identified by protein–protein interaction network and pathway enrichment analysis. We also found high-frequency amplification clonotypes in T and B cells and decreased diversity in T cells in AD. As clone amplification suggested the activation of an adaptive immune response against specific antigens, we speculated that the peripheral adaptive immune response, especially mediated by T cells, may have a role in the pathogenesis of AD. This finding may also contribute to further research regarding disease mechanism and the development of immune-related biomarkers or therapy.

immunology
Altered T cell reactivity to β-amyloid-related antigens in early Alzheimer's disease

Chiara Rickenbach,Anna Mallone,Lars Haeusle,Larissa Frei,Sarina Seiter,Colin Sparano,Tunahan Kirabali,Kaj Blennow,Henrik Zetterberg,Maria Teresa Ferretti,Luka Kulic,Christoph Hock,Roger M. Nitsch,Valerie Treyer,Anton Gietl,Christoph Gericke

DOI: https://doi.org/10.1101/2024.06.04.597424

2024-06-08

Abstract:There is growing evidence that the adaptive immune system and neurodegenerative Alzheimer's disease (AD) are intertwined in multiple ways. Recent studies have reported alterations of the adaptive immune system in early AD stages, such as preclinical AD and mild cognitive impairment (MCI) due to AD. However, the identity of specific antigenic targets and whether the respective response is beneficial or detrimental during disease progression are still open questions. Herein, we describe cross-sectional analyses of blood and cerebrospinal fluid from three different study populations covering early AD stages. We employed high-dimensional mass cytometry, single-cell RNA-sequencing, in vitro T cell secretome analysis, and antigen presentation assays to achieve a comprehensive characterization of adaptive immune cell populations. Our results show that subjects at the stage of asymptomatic, preclinical AD can mount a CD4+ T helper cell response towards β-amyloid peptide and display an early enrichment of cytotoxic CD8+ effector/TEMRA cells in CSF, combined with a less immunosuppressive gene signature of peripheral regulatory T cells. Conversely, in MCI due to AD, we observed increased frequencies of CD8+ effector/TEMRA cells in the periphery, characterized by a pro-inflammatory gene expression profile and an overall decrease in antigen responsiveness. Our results demonstrate the complexity of adaptive immune changes in early AD and suggest that it may be beneficial in the preclinical stage to promote specific CD4+ T cell responses, while in MCI it may be important to therapeutically target CD8+ T cell responses if these prove to be harmful.

Immunology
Peripheral Immune Cells Contribute to the Pathogenesis of Alzheimer's Disease

Li, Chunrong

DOI: https://doi.org/10.1007/s12035-024-04266-6

IF: 5.682

2024-06-07

Molecular Neurobiology

Abstract:Alzheimer's disease (AD) is the most common neurodegenerative disorder with progressive memory and cognitive loss. Neuroinflammation is a central mechanism involved in the progression of AD. With the disruption of the blood-brain barrier (BBB), peripheral immune cells and inflammatory molecules enter into AD brain. However, the exact relationship between peripheral immune cells and AD remains unknown due to various challenges. This study aimed to investigate the potential causal association between peripheral immune cells and AD by using a two-sample Mendelian randomization (TSMR) analysis. We conducted a TSMR to decipher the causal relationship between AD and 731 types of peripheral immune cell parameters from the TBNK, regulatory T cell (Treg), myeloid cell, monocyte, maturation stages of T cell, dendritic cell (DC), and B cell panels. Various analytical methods were employed, including inverse variance weighting (IVW), MR Egger, and weighted median methods. The Cochran's Q statistic, MR-Egger intercept, and MR-PRESSO tests were used to verify the heterogeneity and horizontal pleiotropy of the results. To further verify our results, we also conducted a replication analysis. The analysis identified CD33 on CD14 + monocyte (OR = 1.03; 95% CI, 1.01–1.04; p = 1.14E−04; adjust- p = 0.042) had an increased risk association for AD, which was verified by the replication study. CD33 on CD33dim HLA DR + CD11b- cell (OR = 1.02; 95% CI, 1.01–1.04; p = 2.87E−04; adjust- p = 0.035) had an increased risk association for AD, while secreting CD4 regulatory T cell %CD4 regulatory T cell (OR = 0.97; 95% CI, 0.96–0.99; p = 1.90E−04; adjust- p = 0.046) and CD25 on switched memory B cell (OR = 0.95; 95% CI, 0.92–0.98; p = 2.87E−04; adjust- p = 0.042) were discovered to be related to a lower risk of AD. However, the causal effect of these three immune cells on AD was insufficiently validated in the replication analysis. The MR analysis suggests a potential causal relationship between peripheral immune cells and the risk of AD. Further extensive research is needed on the specific role of peripheral immune cells in AD.

neurosciences
Bone-Marrow-Derived Microglia-Like Cells Ameliorate Brain Amyloid Pathology and Cognitive Impairment in a Mouse Model of Alzheimer's Disease

Shohei Kawanishi,Kazuyuki Takata,Shouma Itezono,Hiroko Nagayama,Sayaka Konoya,Yugo Chisaki,Yuki Toda,Susumu Nakata,Yoshitaka Yano,Yoshihisa Kitamura,Eishi Ashihara

DOI: https://doi.org/10.3233/JAD-170994

Abstract:Microglia, the primary immune cells in the brain, sense pathogens and tissue damage, stimulate cytokine production, and phagocytosis to maintain homeostasis. Accumulation of amyloid-β peptides (Aβ) in the brain triggers the onset of Alzheimer's disease (AD). Accordingly, promotion of Aβ clearance represents a promising strategy for AD therapy. We previously demonstrated that primary-cultured rat microglia phagocytose Aβ, and that transplantation of these cells ameliorates the Aβ burden in brains of Aβ-injected rats. In this study, we demonstrate that stimulation with colony-stimulating factor-1 efficiently differentiates mouse bone marrow cells into bone marrow-derived microglia-like (BMDML) cells that express markers for microglia, including the recently identified transmembrane protein 119. BMDML cells effectively phagocytose Aβ in vitro, with effects comparable to primary-cultured mouse microglia and greater than peritoneal macrophages. RT-qPCR analysis for cytokine mRNA levels revealed that BMDML cells polarize to a relatively anti-inflammatory state under non-stimulated and inflammatory conditions but exert a pro-inflammatory reaction after lipopolysaccharide treatment. Moreover, BMDML cells hippocampally injected into a mouse model of AD are morphologically similar to the ramified and amoeboid types of residential microglia. Comparisons with simulations assuming a uniform distribution of cells suggest that BMDML cells migrate directionally toward Aβ plaques. We also detected Aβ phagocytosis by BMDML cells, concomitant with a reduction in the number and area of Aβ plaques. Finally, we observed amelioration of cognitive impairment in a mouse model of AD after hippocampal injection of BMDML cells. Our results suggest that BMDML cells have potential as a cell-based disease-modifying therapy against AD.

Laboratory synthesis of p-chlorophenyl-L-cysteine and its acetylation by the rat.

B Lymphocytes Ameliorate Alzheimer’s Disease-Like Neuropathology Via Interleukin-35

Pulmonary B Lymphocytes Ameliorate Alzheimer's Disease-Like Neuropathology

Pulmonary B cells ameliorate Alzheimer’s disease-like neuropathology

A butyrolactone derivative 3BDO alleviates memory deficits and reduces amyloid-β deposition in an AβPP/PS1 transgenic mouse model.

Amelioration of Experimental Autoimmune Encephalomyelitis in Alzheimer’s Disease Mouse Models: A Potential Role for Aβ

The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function

Single-cell RNA sequencing reveals B cell–related molecular biomarkers for Alzheimer’s disease

IL-33 ameliorates Alzheimer’s disease-like pathology and cognitive decline

Interferon Regulatory Factor 5 Regulates the Phagocytosis of Microglia and Alleviate Alzheimer's Pathology.

Single-cell transcriptomics reveals colonic immune perturbations during amyloid-β driven Alzheimer's disease in mice

Rejuvenation of peripheral immune cells attenuates Alzheimer's disease-like pathologies and behavioral deficits in a mouse model

The Combined Treatment of Amyloid-Β1-42-stimulated Bone Marrow–derived Dendritic Cells Plus Splenocytes from Young Mice Prevents the Development of Alzheimer's Disease in APPswe/PSENldE9 Mice

CD8 + T cells exacerbate AD-like symptoms in mouse model of amyloidosis

T cell infiltration mediates neurodegeneration and cognitive decline in Alzheimer's disease

Robotic Long-distance Telementoring in Neurosurgery

Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model

Single-Cell RNA Sequencing of Peripheral Blood Reveals Immune Cell Signatures in Alzheimer’s Disease

Altered T cell reactivity to β-amyloid-related antigens in early Alzheimer's disease

Peripheral Immune Cells Contribute to the Pathogenesis of Alzheimer's Disease

Bone-Marrow-Derived Microglia-Like Cells Ameliorate Brain Amyloid Pathology and Cognitive Impairment in a Mouse Model of Alzheimer's Disease